NCT01417806View on ClinicalTrials.gov

Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

June 30, 2016

Study Completion Date

December 31, 2016

Conditions
Small Cell Lung Cancer
Interventions
DRUG

Topotecan and Pasireotide

Topotecan 1.5mg/m2 dailyx5 days and Pasireotide 60 mg IM every 28 days

Trial Locations (1)

33125

RECRUITING

VA. Medical Center, Miami

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

South Florida Veterans Affairs Foundation for Research and Education

FED